Racura Oncology (RAC) AGM 2025 presentation summary

Strategic evolution and clinical pipeline

• Advanced RC220 through multiple clinical stages, targeting AML, EGFR-mutated NSCLC, and cardioprotection in solid tumors.

• New trials include Phase 1a/b for EGFR-mutated NSCLC, Phase 3 AML bridging, and MYC silencing studies.

• RC220 shows promise in combination with doxorubicin for both anticancer efficacy and cardioprotection.

• Over 50 studies and 1,500 patients have contributed to the development history.

• RC220 and RC220+doxorubicin have been safely dosed in patients.

Market opportunity and competitive landscape

• EGFR TKI market exceeds $10 billion annually, with Tagrisso® leading and patent expiry expected in 2032.

• Third-generation EGFR TKIs dominate, but resistance remains a major clinical challenge.

• RC220 aims to delay resistance, offering value to patients and drug marketers.

• MYC dysregulation is linked to resistance in several high-value oncology drug classes.

• TKIs are a rapidly growing market, projected to reach over $100 billion by 2033.

Clinical trial progress and design

• HARNESS-1 Phase 1a/b trial will test RC220 + osimertinib in EGFR-mutated NSCLC, with first patient expected Q1 2026.

• AML Phase 3 trial (RAC-030) offers a rapid, affordable FDA approval path, bridging RC110 to RC220.

• CPACS-1 trial evaluates RC220 for cardioprotection and anticancer synergy in solid tumors.

• All trials are open-label, with frequent data readouts planned for 2026 and 2027.

• Funding for new trials is secured through option conversion, with $5m already raised for HARNESS-1.